Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Metastatic breast cancer

R D Rubens1

  • 1Imperial Cancer Research Fund, Clinical Oncology Unit, Guy's Hospital, London, UK.

Current Opinion in Oncology
|November 1, 1995
PubMed
Summary

Tamoxifen may reduce local breast cancer recurrence but doesn't prevent distant spread or improve survival. New treatments like aromatase inhibitors and taxoids show promise for advanced breast cancer.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The interaction of oestrogen receptor status and pathological features with adjuvant treatment in relation to survival in patients with operable breast cancer: a retrospective study of 2660 patients.

Endocrine-related cancer·2004
Same author

Epirubicin in patients with liver dysfunction: development and evaluation of a novel dose modification scheme.

European journal of cancer (Oxford, England : 1990)·2003
Same author

7. Management of advanced breast cancer.

International journal of clinical practice·2002
Same author

Metastatic eccrine porocarcinoma: response to docetaxel (Taxotere) chemotherapy.

Annals of oncology : official journal of the European Society for Medical Oncology·2001
Same author

Risk of complications from bone metastases in breast cancer. implications for management.

European journal of cancer (Oxford, England : 1990)·2000
Same author

The biology and management of bone metastases.

Critical reviews in oncology/hematology·1999

Area of Science:

  • Oncology
  • Pharmacology
  • Breast Cancer Research

Background:

  • Adjuvant tamoxifen therapy after locoregional recurrence of breast cancer reduces local relapse rates.
  • Tamoxifen's efficacy in metastatic breast cancer, particularly when combined with ovarian function ablation or megestrol acetate, remains limited.
  • Emerging therapies, including aromatase inhibitors and taxoids, are being investigated for breast cancer treatment.

Purpose of the Study:

  • To review the current status and effectiveness of various systemic treatments for breast cancer.
  • To evaluate the role of tamoxifen, aromatase inhibitors, and chemotherapy agents in different breast cancer settings.
  • To highlight advancements in chemotherapy, including taxoids and vinorelbine, and explore novel approaches like high-dose chemotherapy and intra-arterial administration.

Main Methods:

  • Review of existing clinical data and research findings on systemic therapies for breast cancer.
  • Analysis of treatment outcomes for tamoxifen, aromatase inhibitors (formestane, vorozole, letrozole), and chemotherapy agents (paclitaxel, docetaxel, vinorelbine).
  • Exploration of novel treatment strategies, including drug combinations, high-dose chemotherapy with bone marrow support, and intra-arterial chemotherapy administration.

Main Results:

  • Tamoxifen reduces locoregional relapse but does not impact distant metastases or survival in early recurrence.
  • Aromatase inhibitors show effectiveness, with letrozole demonstrating promise in metastatic disease.
  • Taxoids (paclitaxel, docetaxel) exhibit high activity, especially docetaxel as second-line treatment; vinorelbine remains effective. High-dose chemotherapy has not shown improved outcomes in advanced disease.

Conclusions:

  • Tamoxifen has a limited role in preventing distant spread or improving survival in recurrent breast cancer.
  • Aromatase inhibitors and taxoid chemotherapy represent significant advancements in breast cancer treatment, offering improved efficacy.
  • Intra-arterial chemotherapy may provide palliative benefits for selected patients with locoregional disease.

Related Experiment Videos